Dated regulatory and development updates, newest first. Sponsor announcements and approvals are clearly distinguished in each profile.
LY3841136
An investigational amylin-receptor treatment studied for obesity.
The named source supports the status update below. This is not a complete clinical or safety review.
CT-388
Also called CT-388, an investigational treatment for obesity and type 2 diabetes.
The named source supports the status update below. This is not a complete clinical or safety review.
ZP8396
An investigational long-acting amylin analogue studied for obesity.
The named source supports the status update below. This is not a complete clinical or safety review.
Mimrylo
A hepcidin-mimicking treatment for the labeled polycythemia vera population.
United States: Mimrylo for erythrocytosis in adults with polycythemia vera.
Amycretin
Zenagamtide, previously called amycretin, is studied for weight and metabolic outcomes.
The named source supports the status update below. This is not a complete clinical or safety review.
LY3437943
An investigational medicine being studied for obesity, type 2 diabetes and related conditions.
The named source supports the status update below. This is not a complete clinical or safety review.
Lipfendra
An oral peptide medicine for lowering LDL cholesterol in its labeled population.
United States: Lipfendra as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
IBI362
A GLP-1/glucagon medicine with product-specific approvals in China and research in other populations.
China: adult chronic weight management and type 2 diabetes, according to the sponsor. This does not represent US FDA approval.
CT-868
Also called CT-868, an investigational treatment studied in diabetes.
The named source supports the status update below. This is not a complete clinical or safety review.
Icotyde
An oral peptide treatment for the labeled plaque-psoriasis population.
United States: Icotyde for moderate-to-severe plaque psoriasis in adults and patients aged 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
MET-097i
An investigational long-acting GLP-1 treatment also known as MET-097i.
The named source supports the status update below. This is not a complete clinical or safety review.
SS-31
SS-31 is the research name commonly associated with elamipretide, the ingredient in Forzinity.
United States: Forzinity to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, under accelerated approval. Other mitochondrial research and RUO SS-31 vials do not inherit this approval.